Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

93 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Amylyx Pharmaceuticals, Inc. - Special Call
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
BU
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO, ALBRIOZA from the Market, Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
AQ
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
BU
Transcript : Amylyx Pharmaceuticals, Inc. - Special Call
Transcript : Amylyx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
BU
Amylyx Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Transcript : Amylyx Pharmaceuticals, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 02:10 PM
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
BU
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian as Chief Medical Officer
CI
Transcript : Ultragenyx Pharmaceutical Inc. - Analyst/Investor Day
RHYTHM PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K)
AQ
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
GL
Ultragenyx Pharmaceutical Inc. Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
CI
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2022 Earnings Call, Feb 16, 2023
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2022
ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K)
AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2022
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
Transcript : Rhythm Pharmaceuticals, Inc. - Shareholder/Analyst Call
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 02:40 PM
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2022 Earnings Call, May 05, 2022
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
GL
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
GL
Mereo BioPharma : Our Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
PU
Mereo BioPharma : Our Partners Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
PU
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2021 Earnings Call, Feb 10, 2022
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2021 Earnings Call, Nov 02, 2021
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2021 Earnings Call, Aug 02, 2021
CRINETICS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Transcript : Rhythm Pharmaceuticals, Inc. - Shareholder/Analyst Call
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-12-2021 03:30 PM
Ultragenyx to Present at Bank of America Securities Healthcare Conference
GL
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2021 Earnings Call, May 04, 2021
Crinetics Pharmaceuticals : Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
AQ
Ultragenyx Pharmaceutical : Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III
AQ
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
GL
Ultragenyx Pharmaceutical : Announces Approval of Dojolvi in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
AQ
Ultragenyx Pharmaceutical : Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
AQ
Ultragenyx Pharmaceutical : Annual Report (SEC Filing - 10-K)
PU
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2020 Earnings Call, Feb 11, 2021
RHYTHM PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K/A)
AQ
Rhythm Pharmaceuticals, Inc. Announces Committee Appointments
CI
No results for this search
  1. Stock Market
  2. Advanced search
  3. Camille Bedrosian
  4. News